AVEO, Astellas Pharma Decide To Discontinue BATON Breast Cancer Trial

(RTTNews) - AVEO Oncology (AVEO) announced that AVEO and Astellas Pharma Inc. (ALPMY, ALPMY) have jointly decided to discontinue the BATON (Biomarker Assessment of Tivozanib in ONcology) breast cancer clinical trial, a Phase 2 study in patients with locally recurrent or metastatic triple negative breast cancer, due to insufficient enrollment.

The BATON-BC study initiated patient enrollment in December 2012 in a randomized, double-blind, multicenter Phase 2 clinical trial, evaluating the efficacy of tivozanib in combination with paclitaxel compared to placebo in combination with paclitaxel in patients with locally recurrent or metastatic triple negative breast cancer who have received no more than one systemic therapy for advanced or metastatic breast cancer.